MedTrace Logo

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

NCT02208284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-03-04

No results posted yet for this study

Summary

PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06427878 in healthy adult subjects.

Conditions

  • Healthy

Interventions

DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02208284 on ClinicalTrials.gov